Mr. Ori Hadomi, CEO

NASDAQ, TASE: MZOR

June 2017

1

mazorrobot ics .com

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform

Act of 1995 and other securities laws. Forward-looking statements are not historical facts, and are based upon

management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.

Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that

management’s expectations, beliefs and projections will be achieved and actual results may differ materially from what

is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and

uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-

looking statements, including risks detailed in Mazor Robotics Ltd.’s (“Mazor Robotics” or the “Company”) annual

reports on Form 20-F filed with the U.S. Securities and Exchange Commission. The following solution is not yet

cleared for use: ArcAid device.

Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation

to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in

assumptions or changes in other factors affecting forward-looking information except to the extent required by

applicable securities laws. If the Company does update one or more forward-looking statements, no inference should

be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking

statements.

FORWARD LOOKING STATEMENT

2

mazorrobot ics .com

From Vision to Experienced Market Leader

3

230 employees, worldwide Core technology evolution with three generations of commercial products

40+ peer-reviewed articles and strong evidence of improved patient outcomes

Surgical technique used forprecise placement of 160,000+ implants

23,000+ Patients , 100s of surgeons, wide spectrum of procedures

Supporting and serving150+ installations andspine program globally

mazorrobot ics .com

Growing Penetration of US Hospital Market

X

X XX

X

X

X

X

XXXX

X

X

X

Bioskills Lab

Renaissance

Mazor X

4

US Penetration(end of Q1/17)

• 104 Systems Installed in the US

• 43 Mazor X Orders since Launch

• 6 Customers with multiple system orders

• 16 systems ordered by HCA hospital chain

mazorrobot ics .com

Hospital, Geographic and Procedure Diversity

5

20%

19%61%

Revision Deformities Degenerative

10%

9%

76%

5%

Academic Specialty Community ASC

Hospital Types (US) Geographical DistributionProcedure Types

24%

12%64%

APAC Europe US

mazorrobot ics .com

Innovative Core Technology

Foundation of Mazor’s Portfolio of Systems

6

BoneMount

Robotic Guidance

Image Process-

ing

Surgical Tool

Develop-ment

Cross-modality

Image Registr-

ation

Optical Navig-ation

Data Analytics

Software Tools

mazorrobot ics .com

Mazor X

Predictability, Safety and Efficiency through Innovation

7

1. Pre Op Analytics 2. Guided Execution 3. Intra Op Verification

mazorrobot ics .com

Mazor X and Renaissance

Predictability, Safety and Efficiency through Innovation

8

1. Pre Op Analytics 2. Guided Execution 3. Intra Op Verification

mazorrobot ics .com

Mazor X

Predictability, Safety and Efficiency through Innovation

9

1. Pre Op Analytics 2. Guided Execution 3. Intra Op Verification

mazorrobot ics .com 10

mazorrobot ics .com

Evidence-based Medicine

From Accuracy to Outcomes

11

Proven Reduction in Complications and Revisions (1)

___________________________1.Based on published data: Cannestra, e-poster NASS 2014; Kantelhardt, ESJ 2011; Ringel, ESJ 2012, Roser, 2013.

2.Freehand represents the average fluoro radiation exposure during a freehand operation as a baseline for comparison to Renaissance only.

Proven Reduction in Exposure to Radiation (2)

Consistent Accuracy with Improved Outcomes

18.1%

5.8%5.2%

0.9%

Complications Revisions

Free-Hand Mazor

[With Mazor ]…We’ve put in more than 3,000 screws and had zero failures. I do evidence-based surgery, and we’ve actually shown that the risk of running into any kind of complication is reduced three fold compared to minimally invasive cases using “freehand MIS” without the robot, and re-operation rates are also three- to four fold less.

Dr. K. Poelstra , Orthopedist, Destin, FL

mazorrobot ics .com- -

Voice of the Surgeon:

Randomization – “Unethical Following Study Results”

From: XXXXXXXXXXXXXXX

Date: 1/30/17 18:45 (GMT+02:00)

To: Doron Dinstein <doron@mazorrobotics.com>

Subject: Robot Randomization

Doron,

Based on my personal experience and our growing data, I am no longer ethically comfortable randomizing my patients between robotic and

fluoroscopy arms.

I've been thinking about this since our debate at the last investigators meeting. At that time, I felt that randomization was very reasonable as fluoro

is the standard of care in most institutions, but as my experience grows and our data becomes stronger, I no longer feel ethically comfortable

telling patients the two are equivalent in my practice.

Moving forward, I want to enroll all of our appropriate patients in the MIS refresh study robotic arm.

I recognize that this will require some work and probably another trip to the IRB but on the other hand, look at it is a good thing.

Thx.

XXXXXXXXXXXXX

12- Confidential -

mazorrobot ics .com

Accelerated Clinical Utilization

Serving more patients

13

““I find it provides better patient care through enhancement of the surgeon‚ capabilities and it also makes my surgical work easier.”

Dr. Dennis Devito, MD, Atlanta, Georgia

68

70

72

74

76

78

80

82

84

86

2014 2015 2016

Average Number of Procedures per System

Average Procedures per Active SystemAnnual Procedures US

mazorrobot ics .com

Sales Strategy

Building Momentum and Awareness

14

ordered

Trend Illustration

mazorrobot ics .com

Current Business Model

Three Sources

15

Capital Sales (List Prices)

Mazor X: $1,100K

Renaissance: $ 650K

Per Case Revenue

Disposable Kits: List Price $1,500

Synergy fee revenue:* ~$1,000

(*) per procedure with partner implant

Per System Revenue

Annual Service revenues:

10% of system price

mazorrobot ics .com

Mazor and Medtronic Strategic Agreements

Cooperation Successfully Established

16

Marketing

• Joint workstreams and

global workshops focusing

on messaging, targeting and

positioning

Professional Education

• ~150 surgeons participated in

Mazor X training labs

Sales

• 43 Mazor X orders since

commercial launch (Q4/16)

• Pipeline broadened

mazorrobot ics .com

Mazor X - Core of the Surgical Assurance Platform

Short Term Roadmap

17

2018Mazor X Align

2017Mazor X Scan & Plan(Update)

2017Mazor X SIJMazor X Lateral

2018* ArcAidFuturistic rod bendingfor Mazor X-Align plan

*Not yet approved for use

MedtronicCo-Development

2017Medtronic implant planning

mazorrobot ics .com

Medtronic and Mazor Commercial Integration

Assuming Phase II (by Q1/18)

18

Investment1st and 2nd tranches complete: $32M (~8%)

3rd Tranche investment at Mazor’s discretion (up to 15%)

Mazor X SystemsMulti-year commitment to sales quotas at distributor pricing

SalesMedtronic assumes full global responsibility for product, clinical and sales support

Strategic DevelopmentCommitment

Spine non-compete

100sof Systems

↓S&M Expenses

(2016 Actual: $34M)

↑ MZOR/MDT

integrated clinical

procedures

mazorrobot ics .com

A Path to Profitability

19

Revenue

Gross Margin

Operating costs

EBITDA

2016

100%

70.5%

101%

(31%)

~ 2020*

100%

~70%

~50%

~25%

* Assuming entering the phase 2 of Medtronic agreement.

NOL’s – NOL’s at Israeli parent company of ~$90M

mazorrobot ics .com

Exploring Additional Growth Drivers

Leveraging Technology to Make Surgery Predictable and Safe

20

Leverage RoboticsNon-Spine and Future

Leverage Softwareto create OR HUB

New Go-to-MarketStrategy for the Renaissance

mazorrobot ics .com

Financial Results

21

($ in thousands) 2016 2015 2017 2016

Revenue $36,379 $26,096 $11,719 $6,419

Cost of sales $10,330 $5,827 $4,149 $1,654

Gross Profit $26,049 $20,269 $7,570 $4,765

% margin 72% 78% 65% 74%

Operating Expenses

Research and development $5,736 $6,324 $1,792 $2,131

Selling and marketing $33,637 $24,947 $9,893 $6,873

General and administrative $5,697 $4,305 $1,571 $983

Total operating expenses $45,070 $35,576 $13,256 $9,987

% of revenue 124% 136% 113% 156%

Loss from operations ($19,021) ($15,307) ($5,686) ($5,222)

Net loss ($18,668) ($15,385) ($5,232) ($5,112)

Income Statement

Year Ended December 31, 3 Months Ended March 31,

mazorrobot ics .com

Balance Sheet

22

As of March 31, As of December 31,

($ in thousands) 2017 2016

Assets (Unaudited) (Audited)

Cash and Cash equivalent $25,896 $14,954

Short-term investments $32,654 $37,862

Trade receivables $3,076 $8,225

Other accounts receivable $2,109 $1,728

Inventory $5,777 $4,715

Total current assets $69,512 $67,484

Total non-current assets $12,567 $15,241

Total Assets $82,079 $82,725

Current liabilities $18,191 $17,511

Total non-current liabilities $403 $325

Equity $63,485 $64,889

Total liabilities and Equity $82,079 $82,725

Consolidated Statements of Financial Position

mazorrobot ics .com

MAZOR ROBOTICS – ALIGN WITH EXPERIENCE

23

Market AccessSurgery Assurance

Platform

Expanded Co-

Developed Product

offering

Accelerating growth

24